Publicación:
Guía de práctica clínica para tratamiento de fibrilación auricular

dc.contributor.authorForero Supelano, Victor Hugospa
dc.date.accessioned2015-06-30T00:00:00Z
dc.date.accessioned2025-08-05T14:24:28Z
dc.date.available2015-06-30T00:00:00Z
dc.date.available2025-08-05T14:24:28Z
dc.date.issued2015-06-30
dc.description.abstractEl tratamiento de la fibrilación auricular impone retos en cada caso. Nuestro propósito es brindar recomendaciones para el médico en atención primaria. Las fuentes de información principales en la elaboración de la guía fueron estudios primarios y agregativos.En general, el tratamiento de la fi brilación auricular requiere enfoque individualizado y es altamente recomendable aprovechar de manera pertinente las escalas clínicas disponibles para identificación de beneficios y riesgos según las alternativas terapéuticas.Para la toma de deciciones hay dos aspectos clave: 1) determinar justificación para profilaxis antitrombótica, 2) evaluar la estrategia más apropiada: control de frecuencia - control de ritmo. Las recomendaciones estan expuestas en tablas y algoritmos que requieren ser utilizadas según el contexto y características individuales en cada caso.spa
dc.description.abstractSince the management of atrial fibrillation may be difficult in the individual patient, our purpose was to develop simple clinical recommendations to help the primary primary care physicians.SOURCES: Systematic review of the literature with evaluation of data-related evidence and framing of graded recommendations.SYNTHESIS: The management of atrial fibrillation requires individualised evaluation of the risks and benefits of therapeutic modalities, relying whenever possible on simple and validated tools. The two main points requiring a decision in clinical management are 1) whether or not to implement thromboembolic prevention therapy, and 2) whether preference should be given to a “rate control” or “rhythm control” strategy. To assist the physician in making recommendations for the care of an atrial fibrillation patient we propose specific tables and algorithms, with graded recommendations.CONCLUSIONS: On the evidence of data from the literature we propose simple algorithms and tables for the clinical management of atrial fibrillation in the individual patient.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.26752/cuarzo.v21.n1.33
dc.identifier.eissn2500-7181
dc.identifier.issn0121-2133
dc.identifier.urihttps://repositorio.juanncorpas.edu.co/handle/001/343
dc.identifier.urlhttps://doi.org/10.26752/cuarzo.v21.n1.33
dc.language.isospaspa
dc.publisherFundación Universitaria Juan N. Corpasspa
dc.relation.bitstreamhttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/33/32
dc.relation.citationendpage53
dc.relation.citationissue1spa
dc.relation.citationstartpage39
dc.relation.citationvolume21spa
dc.relation.ispartofjournalRevista Cuarzospa
dc.relation.referencesSteinberg B, Kim S, Thomas L, et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2014;129(20):20052012.spa
dc.relation.referencesPenado S, Cano M, Acha O, Hernández J, Riancho J. Atrial fibrillation as a risk factor for stroke recurrence. The American Journal of Medicine. 2003;114(3):206210.spa
dc.relation.referencesAbraham JM, Connolly SJ. Atrial fi brillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev. 2014;19(3):305-13.spa
dc.relation.referencesTaggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for diagnosing atrial fi brillation using 12-lead ECG: A systematic review and meta-analysis. Int J Cardiol. 2015;184C:175-183.spa
dc.relation.referencesShi X-MM, Yuan H-TT, Guo H-YY, Guo J-PP, Shan Z-LL, Wang Y-TT. Electrophysiological characteristics of paroxysmal atrial fibrillation originating from superior vena cava: a clinical analysis of 30 cases. Int J Clin Exp Med. 2015;8(1):240-8.spa
dc.relation.referencesSposato LA, Cipriano LE, Saposnik G, Vargas ER, Riccio PM, Hachinski V. Diagnosis of atrial fi brillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015;14(4):377-87.spa
dc.relation.referencesLuong C, Thompson DJ, Bennett M, et al. Right atrial volume is superior to left atrial volume for prediction of atrial fibrillation recurrence after direct current cardioversion. Can J Cardiol. 2015;31(1):29-35.spa
dc.relation.referencesYoon YE, Oh I-YY, Kim S-AA, et al. Echocardiographic Predictors of Progression to Persistent or Permanent Atrial Fibrillation in Patients with Paroxysmal Atrial Fibrillation (E6P Study). J Am Soc Echocardiogr. 2015.spa
dc.relation.referencesBekwelem W, Misialek JR, Konety S, et al. Echocardiographic measures of cardiac structure and function are associated with risk of atrial fi brillation in blacks: the Atherosclerosis Risk in Communities (ARIC) study. PLoS ONE. 014;9(10):e110111.spa
dc.relation.referencesAl-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate and rhythm-control therapies in patients with atrial fi brillation: a systematic review. Ann Intern Med. 2014;160(11):760-73.spa
dc.relation.referencesOldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fi brillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Annals of internal medicine. 2011;155(10):660-7, W204.spa
dc.relation.referencesDzeshka M, Lane D, Lip G. Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk-Score Acronyms (CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, ATRIA, and More). Clinical Cardiology. 2014;37(10):634-644.spa
dc.relation.referencesHrynkiewicz-Szymanska A, Dluzniewski M, Platek AE, et al. Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. J Thromb Thrombolysis. 2014.spa
dc.relation.referencesAlbertsen I, Rasmussen L, Overvad T, Graungaard T, Larsen T, Lip G. Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Metaanalysis. Stroke. 2013;44(5):1329-1336.spa
dc.relation.referencesSenoo K, Lip GY. Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fi brillation. Semin Thromb Hemost. 2015;41(2):146-53.spa
dc.relation.referencesDentali F, Botto GL, Gianni M, Ambrosino P, Di Minno MN. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: A systematic review and meta-analysis of the literature. Int J Cardiol. 2015;185:72-77.spa
dc.relation.referencesBasili S, Raparelli V, Proietti M, Napoleone L, Ferroni P, Franconi F. Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. Curr Vasc Pharmacol. 2015.spa
dc.relation.referencesCope S, Clemens A, Hammès F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fi brillation stroke prevention trials. Value Health. 2015;18(2):234-49.spa
dc.relation.referencesClaridge SB, Kanaganayagam GS, Kotecha T. Atrial fi brillation guidelines. Don’t forget HASBLED score. BMJ. 2011;342:d3205.spa
dc.relation.referencesScowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013;99(2):127-32.spa
dc.relation.referencesStępińska J, Czerwińska K, Witkowski A, et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J. 2013;20(2):125-33.spa
dc.relation.referencesChiang C-EE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5(4):632-9.spa
dc.relation.referencesChan N, Paikin J, Hirsh J, Lauw M, Eikelboom J, Ginsberg J. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and Haemostasis. 2014;111(5):798807.spa
dc.relation.referencesAhmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther. 2012;10(12):1471-80.spa
dc.relation.referencesChugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fi brillation in developed and developing nations. Glob Heart. 2014;9(1):113-9.spa
dc.relation.referencesAlonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fi brillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102.spa
dc.relation.referencesHealey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120-9.spa
dc.relation.referencesWachter R, Stahrenberg R, Gröschel K. Subclinical atrial fi brillation: how hard should we look? Heart. 2013;99(3):151-3.spa
dc.relation.referencesYoneyama K, Harada T, Ito H, et al. Subclinical atrial fi brillation preceding cardioembolic stroke in a patient with systolic heart failure. Int J Cardiol. 2014;176(3):1036-8.spa
dc.relation.referencesBenezet-Mazuecos J, Rubio JM, Cortés M, et al. Silent ischaemic brain lesions related to atrial high rate episodes in patients with cardiac implantable electronic devices. Europace. 2015;17(3):364-9.spa
dc.relation.referencesHohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-94.spa
dc.relation.referencesCarlsson J, Miketic S, Windeler J, et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fi brillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-6.spa
dc.relation.referencesWyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33.spa
dc.relation.referencesVan Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152(3):420-6.spa
dc.relation.referencesFreudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100(2):247-52.spa
dc.relation.referencesVan Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73.spa
dc.relation.referencesSmit MD, Crijns HJ, Tijssen JG, et al. Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fi brillation data of the RACE II (RAte Control Effi cacy in permanent atrial fi brillation II) study. J Am Coll Cardiol. 2011;58(9):942-9.spa
dc.relation.referencesWeipert KF, Erkapic D, Schmitt J. [Rate and rhythm control in atrial fibrillation: Pharmacological approaches]. Herz. 2015;40(1):16-24.spa
dc.relation.referencesRolf S, Kornej J, Dagres N, Hindricks G. What can rhythm control therapy contribute to prognosis in atrial fi brillation? Heart. 2015.spa
dc.relation.referencesHeidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fi brillation. Europace. 2013;15(5):625-651.spa
dc.relation.referencesRuff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.spa
dc.relation.referencesWallentin L, Lopes RD, Hanna M, et al. Effi cacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166-76.spa
dc.relation.referencesConnolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361(12):1139-51.spa
dc.relation.referencesPatel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med. 2011;365(10):883-91.spa
dc.relation.referencesFreemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, fl ecainide, and propafenone, for the management of atrial fi brillation. Europace. 2011;13(3):329-45.spa
dc.relation.referencesLafuente-Lafuente C, Valembois L, Bergmann J-FF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fi brillation. Cochrane Database Syst Rev. 2015;3:CD005049.spa
dc.rightsRevista Cuarzo - 2015spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/33spa
dc.subjectguide clinical practiceeng
dc.subjectatrial fibrillationeng
dc.subjectembolismeng
dc.subjectanticoagulationeng
dc.subjectbleedingeng
dc.subjectprimary careeng
dc.subjectbrilación auricularspa
dc.subjectembolísmospa
dc.subjectanticoagulaciónspa
dc.subjectsangradospa
dc.subjectguía práctica clínicaspa
dc.subjectatención primariaspa
dc.titleGuía de práctica clínica para tratamiento de fibrilación auricularspa
dc.title.translatedAtrial fIbrillation - practical clinical guidelineeng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublicationspa

Archivos